| Oral rivaroxaban for symptomatic venous thromboembolism Einstein Investigators New England Journal of Medicine 363 (26), 2499-2510, 2010 | 4197 | 2010 |
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism EPE Investigators N Engl j Med 2012 (366), 1287-1297, 2012 | 3071* | 2012 |
| Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2961 | 2017 |
| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ... European heart journal 39 (16), 1330-1393, 2018 | 2799 | 2018 |
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism Hokusai-VTE Investigators New England journal of medicine 369 (15), 1406-1415, 2013 | 2417 | 2013 |
| Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 | 2197 | 2015 |
| Edoxaban for the treatment of cancer-associated venous thromboembolism GE Raskob, N Van Es, P Verhamme, M Carrier, M Di Nisio, D Garcia, ... New England Journal of Medicine 378 (7), 615-624, 2018 | 1948 | 2018 |
| Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ... Ep Europace 17 (10), 1467-1507, 2015 | 1866 | 2015 |
| American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism TL Ortel, I Neumann, W Ageno, R Beyth, NP Clark, A Cuker, BA Hutten, ... Blood advances 4 (19), 4693-4738, 2020 | 1442 | 2020 |
| Idarucizumab for dabigatran reversal—full cohort analysis CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 | 1433 | 2017 |
| European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... Europace 15 (5), 625-651, 2013 | 1321 | 2013 |
| Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 1106 | 2018 |
| Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors SJ Connolly, M Crowther, JW Eikelboom, CM Gibson, JT Curnutte, ... New England Journal of Medicine 380 (14), 1326-1335, 2019 | 1103 | 2019 |
| Andexanet alfa for acute major bleeding associated with factor Xa inhibitors SJ Connolly, TJ Milling Jr, JW Eikelboom, CM Gibson, JT Curnutte, A Gold, ... New England Journal of Medicine 375 (12), 1131-1141, 2016 | 1052 | 2016 |
| Rivaroxaban or aspirin for extended treatment of venous thromboembolism JI Weitz, AWA Lensing, MH Prins, R Bauersachs, J Beyer-Westendorf, ... New England Journal of Medicine 376 (13), 1211-1222, 2017 | 998 | 2017 |
| Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial D Aujesky, PM Roy, F Verschuren, M Righini, J Osterwalder, M Egloff, ... The Lancet 378 (9785), 41-48, 2011 | 778 | 2011 |
| Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease P Holvoet, A Mertens, P Verhamme, K Bogaerts, G Beyens, R Verhaeghe, ... Arteriosclerosis, thrombosis, and vascular biology 21 (5), 844-848, 2001 | 719 | 2001 |
| Factor XI antisense oligonucleotide for prevention of venous thrombosis HR Büller, C Bethune, S Bhanot, D Gailani, BP Monia, GE Raskob, ... New England Journal of Medicine 372 (3), 232-240, 2015 | 695 | 2015 |
| EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... European heart journal 34 (27), 2094-2106, 2013 | 609 | 2013 |
| Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin P Moayyedi, JW Eikelboom, J Bosch, SJ Connolly, L Dyal, ... Gastroenterology 157 (3), 682-691. e2, 2019 | 560 | 2019 |
Thomas VanasscheK U Leuven — University of Leuven, BelgiumVerified email at med.kuleuven.be
